Literature DB >> 2539385

Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection.

M Okano1, G M Thiele, R H Kobayashi, J R Davis, M S Synovec, H L Grierson, H S Jaffe, D T Purtilo.   

Abstract

A 20-month-old male with fulminant infectious mononucleosis and the X-linked lymphoproliferative syndrome (XLP) was studied. Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA) and EBV DNA were detected in various tissues. Despite a combined treatment with acyclovir, immunoglobulin, and methylprednisolone, the patient deteriorated rapidly. Following treatment with recombinant interferon-gamma (IFN-gamma), defervescence occurred and circulating EBNA-positive cells markedly decreased. IFN-gamma prior to treatment ranged from 10.8 to 24.5 U/ml in the patient's serum and increased linearly post exogenous IFN-gamma treatment. His natural killer (NK)-cell activity remained in the normal range throughout his illness but autologous EBV-infected cells were not killed in vitro by his peripheral blood lymphocytes (PBL). These results suggest that patients with the fatal infectious mononucleosis phenotype of XLP may produce endogenous IFN-gamma. Defective cytotoxic T cells against EBV-infected cells seem to be responsible for the fulminant infectious mononucleosis in this patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539385     DOI: 10.1007/bf00917127

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  20 in total

1.  Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation.

Authors:  S Blanche; F Le Deist; F Veber; G Lenoir; A M Fischer; J Brochier; C Boucheix; M Delaage; C Griscelli; A Fischer
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

Review 2.  Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; R L Simmons
Journal:  Transplantation       Date:  1985-05       Impact factor: 4.939

3.  Successful treatment of nasopharyngeal carcinoma with interferon.

Authors:  J Treuner; D Niethammer; G Dannecker; R Hagmann; V Neef; P H Hofschneider
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

4.  Epstein-Barr-virus induced lymphoproliferation. Implications for antiviral chemotherapy.

Authors:  J L Sullivan; P Medveczky; S J Forman; S M Baker; J E Monroe; C Mulder
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

5.  Hepatitis in fatal infectious mononucleosis.

Authors:  R S Markin; J Linder; K Zuerlein; E Mroczek; H L Grierson; B Brichacek; D T Purtilo
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

6.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

Review 7.  Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses.

Authors:  J S Pagano; A K Datta
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

8.  Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon.

Authors:  S H Cheeseman; W Henle; R H Rubin; N E Tolkoff-Rubin; B Cosimi; K Cantell; S Winkle; J T Herrin; P H Black; P S Russell; M S Hirsch
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

9.  X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.

Authors:  J L Sullivan; K S Byron; F E Brewster; S M Baker; H D Ochs
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

10.  Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation.

Authors:  F Hasler; H G Bluestein; N J Zvaifler; L B Epstein
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  7 in total

Review 1.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

Review 3.  Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

Review 4.  The therapy of primary brain lymphoma.

Authors:  F H Hochberg; J S Loeffler; M Prados
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

Review 5.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09

Review 6.  Immune deficiency as a risk factor in Epstein-Barr virus-induced malignant diseases.

Authors:  D T Purtilo; M Okano; H L Grierson
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

Review 7.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.